ProArc Medical

ProArc developed the ClearRing System to treat lower urinary tract symptoms due to BPH providing a unique relief for men with BPH, allowing a quick return to normal life and avoiding invasive, higher-risk surgeries while preserving sexual function.

112% From funding target

אין טבלה 
קמפיין נגמר  אין לחצן 
By: David Nitzan
Successfully funded Public Campaign

Campaign Highlights

Campaign Highlights

Solution for millions of men worldwide

ProArc’s technology addresses a crucial problem for millions of men worldwide. For many, medication is not sufficient, and they must undergo surgery to treat their Benign Prostatic Hyperplasia (BPH) to improve their quality of life. The ClearRing is a potential game-changer enabling a quick and simple procedure for restoring normal and healthy urinary function while eliminating and possible irreversible damage to sexual function that is common with treatment involving prostate tissue removal.


A Rapidly growing market with M&As at high valuations

Market demand for minimally invasive treatments of BPH is rapidly growing driven in large part by a growing population of men over the age of 50. This multi-billion-dollar market has become the target of large healthcare companies, resulting into several significant acquisitions. 


Clinically validated technology, backed by broad IP protection

ProArc’s technology was validated in a first-in-man feasibility multi-center study conducted in Israel and abroad. That study demonstrated the safety profile and potential efficacy of this unique solution, specifically the improvement of urological function without sexual side effects along with quick patient recovery.


The clinical progress of ProArc is accompanied by a strong IP portfolio including already two granted patents in the U.S. and two granted patents in Europe.



Experienced healthcare investors along with IIA and EU SME Horizon 2020 grants

In 2019, ProArc Medical announced that it had been awarded a significant grant from the EU's Horizon 2020 program, in addition to prior funding by the Israel Innovation Authority. The two-year grant supports further R&D and clinical studies with the goal of commercialization of ProArc's ClearRing BPH solution.


Executive Management Team

ProArc is led by seasoned executives with track records of bringing ideas to advanced commercialization, M&A & IPOs. David Nitsan, CEO, Robert Bash, Chairman, and Eli Gendler, CFO have all participated in bringing med-tech startup companies to significant growth and value.



The Idea

The Need

BPH is one of the most common urological diseases among men, affecting 40-50% of men in their 50’s and 80-90% of men in their 80’s, and its prevalence is growing due to the aging of the population. While BPH is a benign (non-cancerous) condition, it can cause loss of productivity and sleep, depression & sexual dysfunction. As a result, this aging population is driving increased healthcare expenditures and the search for cost-effective solutions for improving outcomes. In the field of BPH, patients are demanding enhanced quality of life that preserves sexual function which cannot be delivered by the ‘gold-standard’ of more invasive surgical procedures.



The Solution

ClearRing is positioned to be a game-changer in the treatment of BPH, enabling fast, minimally invasive procedures and recovery, improvement in urological function with preserved sexual function. With ClearRing, there is no need for ongoing BPH medications, or the removal of prostate tissue and the procedure is fully reversible. Minimally invasive BPH procedures are high-value and covered by public and private insurance.



Novelty of the innovation with respect to the state of the art

  • Common BPH treatment options include medication, surgery such as an open prostatectomy, transurethral resection of the prostate (TURP), and minimally invasive therapies such as transurethral needle ablation (TUNA), laser therapy, radiofrequency ablation, urethral lift, water and vapor ablation, and permanent or temporal stents implants
  • The ClearRing system delivers a metallic device, that once implanted into the tissue of the prostate, reshapes the prostate to enable the healthy flow of urine through the urethra. Unlike other implants, the ClearRing does not come into contact with urine that can lead to encrustation or migration nor does it involve any traumatic removal or ablation of prostatic tissue.
  • The implant is delivered via a fully automated delivery Device. A standard electro-surgical (radiofrequency) cutter creates a 3600 degrees groove in the prostate, a dilatation balloon releases the implant into the groove, and the delivery system is removed. The procedure is completed in minutes and can be performed by any urologist experienced in similar therapeutic procedures.

ProArc’s Technology

The system is comprised of a pre-shaped nitinol implant and an easy-to-use automated handheld delivery device. The unique nitinol implant is anatomically shaped for maximum comfort and efficacy. That together with the automated delivery device creates a much more pleasant experience and simpler procedure for the urologist.



ClearRing Procedure Step-by-Step

  1. BPH Affect urinary flow and may even obstruct the urethra
  2. The ClearRing Delivery Device is positioned inside the obstructed urethra
  3. Implant positioning
  4. Creating a circumferential groove
  5. Implant release and Delivery Device withdrawal


Broad IP protection

ProArc has a robust and broad IP portfolio including two granted patents in the U.S., and two granted patents in Europe. ProArc’s patent portfolio gives a broad protection for important aspects concerning the implant, delivery device, and the method of use of the ProArc System.

Moreover, ProArc has additional patent applications pending while continuing to file new applications as new design features are developed.

The technology, IP and the company’s executive management are positioning the company in a favorable position toward successful commercialization and M&A.


ProArc Publications and Citations

ProArc’s solution has been described in published articles in the scientific literature:


ProArc Media Appearances

Prostate reshape implant co ProArc wins $2.2m EU grant, July 2019





David Nitsan
David is a seasoned entrepreneur experienced in early to late-stage sales and exit through M&A in the medical device industry. He was previously CEO of JetPrep (acquired by NYSE:CMD). David has 20 years of experience in the areas of business and product development, clinical trials, regulatory, and sales. David holds BSc. in mechanical engineering and MSc degree in biomedical engineering and an executive MBA.

Robert Bash
Robert has spent the past 15 years leading medical technology companies from R&D to commercialization and strategic transactions in roles that included CEO, CFO & VP Business Development. Robert has led companies to M&A with large international healthcare companies. Before that, Robert was a partner at an Israeli venture capital firm. Robert holds degrees in law from New York University and Georgetown University and a BA from the University of Pennsylvania.

  • Chairman of the Board
Eli Gendler
Eli is a Certified Public Accountant (CPA) with a Master’s in Law. Eli has over 20 years of experience as a CFO in privately held and public companies in the NASDAQ, AIM, and TASE (Vocaltec, Cimatron, Ki-Bi mobile, IFN). As a CFO in traded companies, Eli led IPOs and managed financial and operational aspects of international companies, while complying with the regulations of the Securities and Exchange Commission (SEC).

  • Key Employee
Sefi Shachrur
Acting VP R&D (Israel R&D Director of Integer)
Founder & owner of Inomec (acquired by Integer) – a Medical Device R&D and production services firm in Israel. Expert in medical device (minimal invasive delivery systems and surgery tools) development for multi-disciplinary systems and transfer to production including a strong understanding of regulation and QA processes. B.Sc. mechanical engineer from Technion Technological Institute of Israel. Nowadays, as part of his role at Integer, Sefi leads all the development processes of the ClearRing System.

Frank Mastandrea
Medical Advisor and Director
Dr. Frank Mastandrea, M.D. is a urology specialist in Tampa, Florida (USA). He currently practices at Florida Urology Partners, LLP, affiliated with St Joseph‘s Hospital of Tampa, FL. Dr. Mastandrea, together with a number of his urologist partners at Florida Urology Partners, invested privately in ProArc.

  • Director
  • Advisor
Dr. Yair Feld
Medical Director & Founder
Dr. Feld has over 20 years of experience leading innovative research and development projects. He currently is practicing medicine at Rambam Medical Center. He is a serial entrepreneur having founded sever medical technology companies. Yair received his M.D and PhD from the Technion-Israel Institute of Technology.

  • Founder
  • Director
  • Advisor
Sew-Wah Tay
Regulatory and Clinical Advisor
Dr. Tay is supporting ProArc in the field of FDA regulatory and clinical affairs. Dr. Tay founded Libra Medical Inc. in January 2007 after 20 years of experience in the medical device industry with specific experience in the BPH industry where she led the regulatory and clinical affairs for NxThera that was acquired by Boston Scientific. She holds an M.S. in chemical engineering, an M.S. in food science, and a Ph.D. in the interdisciplinary area of biomaterials, all from MIT.

  • Advisor
Ilan Leibovitch
Medical Advisor
Prof. Ilan Leibovitch is the head of the Department of Urology at Meir Medical Center. He treats renal malignancies, including organ surgery: prostate, testicular, and bladder cancer, including surgery for the reconstruction of the bladder. Prof. Leibovitch is an author of more than a hundred scientific papers, published in leading medical journals and books dedicated to the prostate gland.

  • Advisor



Currently there are no updates in this pitch

The financing rounds made through the ExitValley platform are in accordance with a model of statutory exemption from publishing a prospectus pursuant to sections 15A(A)(1) and 15A(A)(7) to the Israeli companies law - 1965.
Under our model, the disclosure of detailed information on the company and information about the investment in each round of financing are limited to not more than 35 investors which are not qualified investors and the round of financing in not in the format of an offering arrangement ("רכז הצעה") as defined in the securities law
Follow us